Literature DB >> 31800679

Protective efficacy of combined use of parecoxib and dexmedetomidine on postoperative hyperalgesia and early cognitive dysfunction after laparoscopic cholecystectomy for elderly patients.

Xiaoxuan Du1, Feng Song2, Xueqiang Zhang3, Shanshan Ma3.   

Abstract

PURPOSE: To investigate efficacy of combined use of parecoxib and dexmedetomidine on postoperative pain and early cognitive dysfunction after laparoscopic cholecystectomy for elderly patients.
METHODS: The present prospective randomized controlled study included a total of 80 patients who underwent laparoscopic cholecystectomy surgery during January 2016 to November 2017 in our hospital. All patients were randomly divided into 4 groups, the parecoxib group, the dexmedetomidine group, the parecoxib and dexmedetomidine combined group, and the control group. Demographic data and clinical data were collected. Indexes of heart rate (HR), mean arterial pressure (MAP), levels of jugular venous oxygen saturation (SjvO2) and jugular venous oxygen pressure (PjvO2) were recorded at different time points before and during the surgery. The mini-mental state examination (MMSE) score, Ramsay score and Visual Analogue Score (VAS) were measured.
RESULTS: Levels of both SjvO2 and PjvO2 were significantly higher in parecoxib group, dexmedetomidine group and the combined group than the control group. Meanwhile, levels of both SjvO2 and PjvO2 in the combined group were the highest. VAS scores were significantly lower in the combined group than all other groups, and total patient controlled intravenous analgesia (PCIA) pressing times within 48 h after surgery were the lowest in the combined group. Both Ramsay and MMSE scores were the highest in the combined group compared with other groups, while were the lowest in the control group.
CONCLUSION: The combined use of parecoxib and dexmedetomidine could reduce the postoperative pain and improve the postoperative sedation and cognitive conditions of patients after laparoscopic cholecystectomy.

Entities:  

Year:  2019        PMID: 31800679     DOI: 10.1590/s0102-865020190090000005

Source DB:  PubMed          Journal:  Acta Cir Bras        ISSN: 0102-8650            Impact factor:   1.388


  3 in total

Review 1.  The Role of miRNAs in Dexmedetomidine's Neuroprotective Effects against Brain Disorders.

Authors:  Codrin-Constantin Burlacu; Maria-Adriana Neag; Andrei-Otto Mitre; Alexandru-Constantin Sirbu; Andrei-Vlad Badulescu; Anca-Dana Buzoianu
Journal:  Int J Mol Sci       Date:  2022-05-13       Impact factor: 6.208

2.  Effect of Systemic Lidocaine on Postoperative Early Recovery Quality in Patients Undergoing Supratentorial Tumor Resection.

Authors:  Kai Zhao; Yushan Dong; Gaowei Su; Yaolin Wang; Tao Ji; Nanling Wu; Xiaojie Cui; Wenzhan Li; Yanming Yang; Xiuxia Chen
Journal:  Drug Des Devel Ther       Date:  2022-04-22       Impact factor: 4.319

3.  Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS.

Authors:  Jie Hu; Bing-Feng Lv; Wen-Jing Guo; Bo-Wen Wang; Di Miao; Xiang-Jun Qiu; Xing-Peng Chen
Journal:  Biomed Res Int       Date:  2020-08-06       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.